Ris-Rez Delivers Again: GSK's ADC Hits Primary Endpoint in Second Phase III Trial, Now in Osteosarcoma
GSK sits 47% above its 52-week low of $36.75.
Summary
Hansoh Pharma, GSK's licensor, announced that the phase III ARTEMIS-011 trial of Ris-Rez in relapsed osteosarcoma met its primary endpoint of progression-free survival, with a consistent benefit in overall survival and no new safety signals. The results bolster confidence in Ris-Rez's broad potential and support a regulatory filing in China.
Key Events · Product Development and Regulatory · GSK
-
Phase III Osteosarcoma Trial Met Primary Endpoint
Conducted in China, ARTEMIS-011 demonstrated a statistically significant and clinically meaningful improvement in progression-free survival for Ris-Rez versus chemotherapy in relapsed osteosarcoma patients who had received at least two prior lines of therapy.
-
Consistent Benefit Across Secondary Endpoints
Overall survival also favored Ris-Rez, with a safety profile consistent with prior findings and no new safety signals identified.
-
Only B7-H3 ADC with Positive Phase III Data in Multiple Tumors
Following recent pivotal data in small-cell lung cancer, these results make Ris-Rez the only B7-H3-targeted ADC to deliver positive phase III outcomes across multiple tumor types.
-
Regulatory Submission Planned in China
Hansoh Pharma will use the ARTEMIS-011 data for regulatory submission in China, where Ris-Rez could become the first approved therapy for late-line relapsed osteosarcoma.
Analysis · GSK · Life Sciences
Ris-Rez continues to build a compelling late-stage profile, with positive phase III data in osteosarcoma arriving on the heels of pivotal SCLC results. It now stands as the only B7-H3-targeted ADC to deliver positive phase III outcomes across multiple tumor types. Osteosarcoma, a rare bone cancer with no approved therapies beyond two prior lines, represents an area of high unmet need. GSK holds ex-China rights and is advancing a global sarcoma trial, positioning Ris-Rez as a potential blockbuster oncology asset. The data will support a regulatory submission in China by partner Hansoh, while GSK's own development program expands across lung, prostate, and other solid tumors.
How filings like this one have moved
In the 30 days to Sep 13, 2026, 35.3% of the 1324 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.36%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, GSK was trading at $54.02 on NYSE in the Life Sciences sector, with a market capitalization of approximately $104.4B. The 52-week trading range was $36.75 to $61.70. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.